Scientists found that mesenchymal stromal cells (MSCs) — cells that have similar properties to stem cells — individually coated with a soft microgel were able to reverse established lung tissue scarring in a mouse model of pulmonary fibrosis. Their findings were reported in…
News
Nuformix announced it has received notice that it can expect to be granted a U.S. patent for its potential inhaled therapy for idiopathic pulmonary fibrosis (IPF). NXP002, the company’s lead pre-clinical asset, is a new formulation of tranilast, an antiallergic medication that is under investigation for its…
Adding two broad spectrum antibiotics — co-trimoxazole or doxycycline — to standard care does not significantly delay hospitalization or prolong survival in adults with idiopathic pulmonary fibrosis (IPF), according to data from one of the largest clinical trials in IPF. While several studies have shown that changes in lung…
Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies, which might mean the therapy can work even when IPF is linked to an autoimmune disease, a study suggests. The study, “Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according…
The first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating RXC007, Redx Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other fibrotic, or scarring-related, conditions. “The start of our first clinical study with RXC007 is an important milestone for Redx,” Lisa…
Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its idiopathic pulmonary fibrosis (IPF) program and conduct collaborative research. The biopharmaceutical’s IPF program focuses on developing senolytics, or small molecules that target harmful senescent cells. These cells increase inflammation, fibrosis…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans…
The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the week’s pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000in grants, totaling up…
